Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer: A Randomized Trial

CONTEXT: Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) is the standard adjuvant therapy for resected stage III colon cancer. Adding cetuximab to FOLFOX benefits patients with metastatic wild-type KRAS but not mutated KRAS colon cancer. OBJECTIVE: To assess the potential benefit of cetuximab add...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Alberts, Steven R., Sargent, Daniel J., Nair, Suresh, Mahoney, Michelle R., Mooney, Margaret, Thibodeau, Stephen N., Smyrk, Thomas C., Sinicrope, Frank A., Chan, Emily, Gill, Sharlene, Kahlenberg, Morton S., Shields, Anthony F., Quesenberry, James T., Webb, Thomas A., Farr, Gist H., Pockaj, Barbara A., Grothey, Axel, Goldberg, Richard M.
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3442260/
https://ncbi.nlm.nih.gov/pubmed/22474202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2012.385
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares